Host-specific reactions to NKG2D CAR treatment were also responsible for endogenous anti-tumor response, as enhanced CD4+ and CD8+ tumor-specific memory responses [77], increased activation of host T-cells and NK cells at the tumor site [72], and an increase in the number of tumor-specific host CD4+ T-cells accumulating in the tumor and the draining lymph nodes were observed [78]. Here, KLRK1 is linked to neoplasm.